Business Context and Reporting Period
This Form 8-K is a current report filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) on June 21, 2018, regarding events occurring on June 19, 2018. The registrant is a Delaware corporation and an emerging growth company focused on oncology drug development.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change is the promotion of Steven M. Fruchtman, M.D., to President, effective June 19, 2018. Dr. Fruchtman previously served as Chief Medical Officer and Senior Vice President, Research and Development since January 2015. He will retain his previous responsibilities until a replacement is hired.
Guidance, Outlook, and Compensation Details
The filing details an amended and restated employment agreement for Dr. Fruchtman with the following terms:
- Base Salary: $510,000 annually.
- Signing Bonus: $200,000, subject to repayment if employment terminates before June 19, 2019, for cause or without good reason.
- Stock Options: An initial award of 300,000 shares (subject to plan approval) and potential annual awards based on performance goals.
- Annual Bonus: Target of 50% of base salary based on individual and company performance.
- Severance Provisions:
- Voluntary resignation within 3 months of a new CEO appointment: 7 months' salary and full vesting of options.
- Termination without cause or for good reason (outside change in control): 9 months' salary and target bonus, plus 9 months of COBRA coverage.
- Termination within 12 months of a change in control: 12 months' salary and target bonus, plus 12 months of COBRA coverage.
- Restrictions: Includes non-solicitation and non-competition clauses for 12 months post-employment.
Investor Verification Checklist
- Verify the approval status of the 2018 Omnibus Incentive Compensation Plan required for the 300,000 share option grant.
- Confirm the company's current cash position to assess the impact of the $200,000 signing bonus and increased salary obligations.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Monitor the timeline for hiring a replacement for the Chief Medical Officer and R&D roles.